Federal Circuit: Skepticism of FDA Supports Finding of Nonobviousness and Patent Eligibility Not Within Scope of Appeal of an IPR

Apr 30, 2019

Reading Time : 2 min

The claims of the ’209 Patent were challenged in three petitions for inter partes review (IPR), but in each case the Board concluded that there was no motivation to combine the asserted prior art and that “skepticism of others,” namely the FDA, supported a finding of nonobviousness. On appeal, the Federal Circuit held that the Board’s findings were supported by the evidence and affirmed the Board’s final written decisions.

As to motivation to combine, the Federal Circuit agreed with the Board that one of the prior art references was limited to cardiovascular concerns and only generally mentioned cancer. As such, there was no motivation to combine references across fields of treatment. With respect to the Board’s findings regarding “skepticism of others,” the patent challengers argued on appeal that the FDA’s concern regarding the claimed treatment was insufficient because the FDA had allowed the patent owner to go forward with clinical trials. The Federal Circuit disagreed and noted that there is a range as to what constitutes skepticism—from a belief an invention is impossible to a belief that it is unlikely. In this case, the Federal Circuit found that the FDA’s concerns expressed during the clinical trials amounted to skepticism.

Finally, on appeal the patent challengers argued that the claims of the ’209 Patent were not directed to patentable subject matter and that, because patent eligibility is a question of law, this was an issue that could be raised properly on appeal. The Federal Circuit disagreed stating that Congress expressly limited IPRs to grounds that can be raised under 35 U.S.C. §§ 102 and 103. Thus, because patent eligibility arises under § 101, the Federal Circuit held that it cannot be addressed on appeal of an IPR.

Practice Tip: In an IPR, a petitioner should explain thoroughly the motivation to combine the prior art references, especially when those references may be viewed as relating to different fields, even if those fields seem closely related. Moreover, “skepticism of others”—as a secondary consideration of nonobviousness—may not require evidence of technical impossibility, but a simple showing of concern or surprise may suffice.

Neptune Generics, LLC v. Eli Lilly & Company, 2018-1257, 2018-1258 (Fed. Cir. Apr. 26, 2019); Mylan Laboratories Limited, et al. v. Eli Lilly & Company, 2018-1288, 2018-1290 (Fed. Cir. Apr. 26, 2019).

Share This Insight

Previous Entries

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 10, 2024

In a patent case containing a variety of federal and state law claims, the District of Massachusetts retained supplemental jurisdiction over the state law claims even after all the federal law claims were dismissed.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.